Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Central Nervous System

Categories

[Search within category]

NOVEL BRAIN TECHNOLOGY FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS USING ELECTRICAL STIMULATIONS

This invention is a novel technology developed to treat a patient’s neurological and/or psychiatric conditions. It consists of a system of implantable devices and computational algorithms that not only has autonomous control in sensing and stimulation of electrical signals in the patient’s brain, but also enables interactions with the external environment, thereby enhancing training and learning.

Biomarker of Dyskinesia to Customize Medication or Deep Brain Stimulation for Parkinson's Disease Patients

This invention has provided methods for detecting dyskinesia in Parkinson’s disease patients and provided a way to titrate current treatment to maximize benefits while minimizing side effects.

Mobile Phone Based Fluorescence Multi-Well Plate Reader

UCLA researchers have developed a novel mobile phone-based fluorescence multi-well plate reader.

Pathway-Dependent Inhibition Of Proteopathic Seed Transmission

UCLA researchers in the Department of Neurology have developed a novel approach to stop the propagation of proteopathic diseases, which could be applied to wide range of neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease.

Immunotherapy Against Aß-Mediated Inhibition of ADAM10 Activity

UCLA researchers in the Department of Neurology have developed a novel immunotherapy targeting a previously unexplored pathway of Aβ toxicity in Alzheimer’s disease.

Immunotherapy for Treatment of Neuromyelitis Optica (NMO)

This invention comprises compositions and methods for treatment of neuromyelitis optica (NMO) spectrum disorders using anti-aquaporin-4 (AQP4) antibody lacking effector function.

Nell-1 Regulates Neurogenesis And Nervous System Function

UCLA researchers in the Division of Plastic and Reconstructive Surgery at the Geffen School of Medicine and researchers at the School of Dentistry have identified neural EGFL Like 1 (Nell-1) protein as an essential molecule involved in neurogenic development and nervous system functional regulation.

Generation of a New Animal Model for Studying Multiple Sclerosis

Human multiple sclerosis affects millions of people and is predominately a chronic immune-mediated disease of the central nervous system (CNS). The disease is estimated to affect 2-3 million in 2013 on a global basis. The value of the multiple sclerosis therapeutics market will rise from $17.2 billion in 2014 to approximately $20 billion by 2024. However, the pathogenic mechanisms underlying disease progression are not understood and currently there is no cure for the disease. Therapeutic drugs are developed using two classical experimental autoimmune/allergic encephalomyelitis (EAE) models. Experimental autoimmune/allergic encephalomyelitis (EAE) is the most extensively studied animal model for human MS. However, EAE mainly affects spinal cord white matter, whereas human MS displays demyelination and axonal injuries in the cerebral and cerebellar cortex. In addition, human MS progression cannot be studied in EAE.The second major animal model is RNA virus (TMEV, Theiler’s murine encephalomyelitis virus) induced demyelination, which is considered as a more relevant model to human MS. However, demyelination is caused by persistent TMEV virus infection that is not observed in human MS. Additionally, the TMEV virus can only infect mouse, but not other rodents or primates, limiting its utilization in establishing MS models in other species. Because the TMEV virus is a mouse pathogen, animal facilities often refuse such studies. A new animal model that more closely resembles the pathology of human multiple sclerosis is urgently needed.

The Use of Voltammetry Based Assessment of Neurotransmitters and Metabolites in Vivo

UCLA researchers in the Departments of Medicine, Radiology and Bioengineering have developed novel methods for monitoring cardiac autonomic function in vascular and tissue compartments by measuring neurotransmitters and metabolites in vivo.

Anti-Oxidant Response Modifiers as Treatment for HIV-Associated Neurocognitive Disorder

UCLA researchers have identified anti-oxidative response modulators as a potential treatment for HIV-associated neurocognitive disorders (HAND).

Novel Anti-Bacterial, Anti-Fungal Nanopillared Surface

Medical devices are susceptible to contamination by harmful microbes, such as bacteria and fungi, which form biofilms on device surfaces. These biofilms are often resistant to antibiotics and other current treatments, resulting in over 2 million people per year suffering from diseases related to these contaminating microbes. Death rates for many of these diseases are high, often exceeding 50%. Researchers at UCI have developed a novel anti-bacterial and anti-fungal biocomposite that incorporates a nanopillared surface structure that can be applied as a coating to medical devices.

Peripheral Nerve Repair By Peptide Amphiphile Nanofibers.

UCLA researchers in the Department of Surgery have developed a novel method that promotes directed nerve growth and peripheral nerve regeneration using peptide amphiphile (PA) nanofibers. The combination of conduit and PA nanofiber scaffold offers greater success than currently used methods of bridging with empty conduits. This novel approach may become a substitute for nerve graft for clinical use in the treatment of peripheral nerve injuries.

Accessing Spinal Network To Enable Respiratory Function

UCLA researchers have developed a novel method to stimulate the central nervous system (CNS) to restore normal breathing in persons with brain or spinal cord injury or disease resulting in impaired breathing ability.

Sieve Container For Contactless Media Exchange For Cell Growth

Media that contains nutrients and growth factors is necessary to grow all types of cells, a process that is widely used in many fields of research. Such media should be routinely changed either to different media or a fresh batch of the same media. This change currently involves either using a pipette to transfer cells from their current dish of media to a new dish, or aspirating the media out of the dish and replacing it with new media. Both methods have inherent risks to stressing and damaging the cells. Researchers at UCI have developed a unique dish for growing cells that allows for safer aspiration of the old media, which reduces stress and damage to the cells.

Treatment Of Tau-Related Dementia

The use of farnesyltransferase inhibitors (FTIs) has shown great promise in preventing tau neurodegeneration in models, offering a new avenue for treatment exploration.

Non-Invasive Method For Determination Of Tissue Electrical Conductivity

UCLA researchers in the UCLA Semel Institutes of Neuroscience and Behavior have developed a non-invasive method to locate and estimate electrical currents in organs such as the brain and heart.

Fully Automated Localization Of EEG Electrodes

UCLA researchers have developed an algorithm for precisely locating EEG electrodes with respect to the patient’s brain.

Microbial Mediators Of The Beneficial Effects Of The Ketogenic Diet

UCLA researchers have identified a strategy to manipulate the gut microbiome to mimic the effects of a ketogenic diet, as a treatment for CNS disorders and metabolic diseases.

Retractable Step Cannula For Brain Delivery Of Therapeutics

An adjustable step cannula to minimize therapeutic agent leakage and maximize on-target drug delivery. This new cannula design improves brain drug delivery over current fixed-length step cannulas.

Methods For The Identification And Targeting Of Brain Regions And Structures

A UCLA physician has developed a method to identify regions of the brain using Diffusion Tensor Imaging MRI to locate afferent and efferent neural tracts that lead to and from the specific region of interest. This technique will improve the accuracy and safety of brain treatments, such as electrical brain stimulation and ultrasound imaging.

Increasing Brain Excitability For Recovery After Stroke

Researchers at UCLA have developed an effective treatment that promotes Central Nervous System (CNS) repair in damaged brains following stroke, trauma or neurodegenerative disease.This novel therapeutic approach has shown tremendous promise, and can significantly impact CNS injury treatment.

Apoe4-Targeted Theraputics That Increase Sirt1

UCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.

Combination Of Approved Alzheimer's Drugs With Metabolic Enhancement For Neurodegeneration (MEND) To Comprise A Therapeutic System

UCLA researchers in the Department of Neurology have developed a novel therapeutic program for Alzheimer’s disease, based on the combination of existing AD drugs and a program to enhance metabolic activity.

  • Go to Page: